If You Invested in Protext Mobility Inc (TXTM)

Protext Mobility, Inc. (OTC: TXTM) is a biotechnology company focused on plant-based therapeutics and highly bioavailable botanical formulations. According to multiple company disclosures, Protext concentrates on the research, testing, and development of nanotechnology-based botanical products for nutraceutical and pharmaceutical applications, using proprietary live plant extraction technologies designed to increase bioavailability and support wellness and health needs globally.

Business Focus and Core Activities

Protext states that, through its prior acquisitions, it has engaged in the development of highly bioavailable botanical products and all‑natural ingredients formulated for nutraceutical and pharmaceutical uses. The company describes itself as an emerging biotechnology and alternative wellness business, working with live plant extraction technology to create formulations that aim to deliver plant-based therapeutics with enhanced absorption characteristics.

Company communications describe the use of proprietary live plant extraction technology, sometimes referred to as kettle extraction technology, in combination with nanotechnology approaches. This platform is presented as central to Protext’s efforts to produce botanical formulations and active pharmaceutical ingredients (APIs) from plant materials, including Genus Cannabis Sativa and other medicinal plants, with significantly increased bioavailability compared to standard extracts.

Plant-Based Therapeutics and Botanical Formulations

In its news releases, Protext explains that it is focused on plant-based therapeutics and botanical formulations that can be used in nutraceutical and pharmaceutical contexts. The company highlights work with Genus Cannabis Sativa, including research, testing, and development of products derived from this plant. Protext has discussed CBD-rich applications, including CBD flower, biomass, and CBD-based health and wellness products, within its broader botanical product strategy.

The company also references an interest in other indigenous plant flora with medicinal properties. It has described research and development using its live plant extraction technology on additional medicinal plants, with the goal of creating natural plant-based medicine that offers higher bioavailability than many existing products.

Live Plant Extraction Technology and Bioavailability

Protext’s disclosures emphasize its live plant extraction technology, which has been tested using kettle extraction equipment. The company reports that this technology has been used to produce full-spectrum cannabinoid emulsions from live Genus Cannabis Sativa plants under conditions intended to minimize conversion of non‑psychoactive precursor acids (such as THC‑A) into psychoactive forms. According to the company, earlier clinical work with similar extraction equipment on other medicinal plants demonstrated extracts with substantially increased bioavailability compared to standard extracts.

In various communications, Protext has described results indicating that its extraction approach can yield botanical extracts with significantly higher bioavailability and potency per unit volume than many conventional extracts. The company presents this as a foundation for developing plant-based therapeutics that may require lower dosages to achieve comparable effects, while potentially extending the duration of action in the body.

Genus Cannabis Sativa, Seeds, and Supply Arrangements

Protext has disclosed activities related to Genus Cannabis Sativa seeds and biomass. In one shareholder update, the company reported that its President and Chairman contributed a substantial quantity of Genus Cannabis Sativa seeds to Protext as an equity contribution, which the company recorded as seed inventory. The company also described a seed multiplication program, in which seed inventory is central to its operational planning.

In another disclosure, Protext outlined a supply agreement with its President and Chairman, in his capacity as an independent fourth‑generation farmer controlling a large farm in South Africa and certain permits related to cultivation and import/export of agricultural products, including Genus Cannabis Sativa. Under this arrangement, the farmer and associated team are responsible for planting hemp crops derived from Genus Cannabis Sativa seeds at a farm he controls. Protext states that it does not own or control any farm and does not hold permits itself, but may benefit from permits controlled by its Chairman in his individual capacity, although there is no guarantee this will occur.

The company has also described plans, as part of its general business, to fulfill orders and ship products to end customers around the world, including biomass derived from hemp, raw or processed CBD, and finished health and wellness products containing CBD derived from Genus Cannabis Sativa. These shipments are described as being made in compliance with the rules and regulations of each jurisdiction involved.

Research, Testing, and Development

Protext has repeatedly stated that it is engaged in research, testing, and development of botanical products and live plant extraction processes. The company has referenced work conducted at permitted farms in South Africa, where live Genus Cannabis Sativa plants were processed using the proprietary kettle extraction system. According to the company, these tests demonstrated that full‑spectrum cannabinoids can be extracted while retaining non‑psychoactive precursor forms and that the resulting extracts can be formulated as nano‑emulsions.

Protext has also discussed applying the same extraction technology to other medicinal plants, with prior research and clinical trials cited as evidence that the technology can increase bioavailability multiple times compared to standard extracts. The company presents this as a potential basis for natural pharmaceuticals derived from plant sources.

Real-World Assets, Tokenization, and Stablecoin Concepts

In more recent communications, Protext has described an approach in which active pharmaceutical ingredients (APIs) produced from plant materials, including CBD-based APIs, are treated as real‑world assets (RWA) on its balance sheet under IFRS/GAAP frameworks. The company has stated that contributions and support under a Letter of Intent (LOI) with TruLeaf, such as sample products, initial inventory allocations, and infrastructure-related assistance, are recognized as income or gains under IFRS guidelines.

Protext has further stated that APIs and other real‑world assets can be tokenized as RWA tokens, creating cash‑equivalent assets that the company views as enhancing its balance sheet. In one news release, Protext indicated that CBD APIs recognized as real‑world assets could potentially support the creation of a stablecoin, with possible future applications in staking, investment, or liquidity. These concepts are presented as part of the company’s monetization ecosystem but are described in the context of potential and planned applications rather than as completed programs.

Zero-Waste and Circular Economy Model

Protext has described a zero‑waste, green, circular economy model as part of its strategy. In this model, plant-based real‑world assets, including APIs and carbon credits, are described as being convertible into RWA tokens. The company presents this framework as a way to combine sustainability objectives with financial structuring of plant-based assets, though detailed operational metrics are not provided in the available disclosures.

Advisory Board and Human Capital

The company has emphasized the importance of human capital, government relationships, and advisory expertise in its business. Protext has highlighted the formation of an Advisory Board composed of business leaders and strategic advisors intended to provide guidance on business development, strategic opportunities, and global market insights. The Advisory Board is presented as supporting transparency, governance, and long‑term shareholder value.

In one announcement, Protext noted the appointment of an Ambassador of South Africa to Chad to its Advisory Board, describing this as an example of international advisory participation. The company frequently refers to the value of its management’s experience, relationships, and permits controlled by individuals associated with its operations, particularly in relation to Genus Cannabis Sativa activities in South Africa.

Investor Relations, Transparency, and Governance

Protext has made multiple statements about transparency, governance, and investor communication. The company has referenced the removal of a caveat emptor designation by OTC Markets and its attainment of OTCID Basic Market status, noting that it is current in its corporate filing information with OTC Markets Group.

The company has also announced initiatives such as an Investor Relations presentation and microsite designed to provide shareholders with access to financial data, regulatory filings, press releases, and investor webcasts. Additionally, Protext has indicated that it is voluntarily submitting its disclosure filings through the SEC’s EDGAR system, even though this is not required under the OTC Markets Alternative Reporting Standard, as part of its efforts to align with certain regulatory best practices.

In more recent updates, Protext has stated that it has engaged an independent consultant to resume voluntary EDGAR filings and is upgrading its corporate website using live‑update technology. The company presents these steps as measures to enhance transparency, regulatory compliance, and shareholder engagement.

Financial Reporting Framework and Exchange Ambitions

Protext has reported that its financial statements for certain years have been audited under International Financial Reporting Standards (IFRS), and that additional filings are in progress. The company has described itself as administratively compliant and has referenced ambitions related to filing a Form 10 with the SEC and pursuing an uplisting to a major global exchange. These statements are presented as goals and ambitions rather than completed actions.

In its communications, Protext has also discussed the impact of foreign exchange (FX) movements on the value of seed inventory denominated in South African rand, describing this as a potential translational benefit in future reporting cycles. The company links FX effects, API monetization, and seed multiplication activities to its overall financial planning and reporting under IFRS.

Corporate Status and Trading

Based on the available news releases, Protext Mobility, Inc. trades on the OTC market under the symbol TXTM. The company has addressed past caveat emptor designations and has reported their removal by OTC Markets Group. There is no indication in the provided materials of a completed delisting from the OTC market, a completed merger that eliminated the public entity, or a bankruptcy filing. The company has publicly discussed potential uplisting objectives and voluntary alignment with certain regulatory practices.

Summary

In summary, Protext Mobility, Inc. (OTC: TXTM) describes itself as a biotechnology and alternative wellness company centered on plant-based therapeutics, live plant extraction technology, and highly bioavailable botanical formulations. Its disclosures emphasize work with Genus Cannabis Sativa and other medicinal plants, the use of proprietary kettle extraction and nanotechnology approaches, and a focus on nutraceutical and pharmaceutical applications. The company highlights its research and testing activities, human capital and advisory relationships, evolving investor relations infrastructure, and a conceptual framework that combines plant-based assets with real‑world asset accounting and tokenization concepts, all within a stated commitment to transparency and governance.